autologous anti-CD83 CAR T-cells / Roswell Park Comprehensive Cancer Center - LARVOL DELTA

Roswell Park Launches Exclusive CD83 CAR T-Cell Clinical Trial for Patients with Relapsed or Refractory AML (Newswise) - "Roswell Park Comprehensive Cancer Center has launched an exclusive phase 1 clinical trial of a new chimeric antigen receptor (CAR) T-cell therapy for patients whose acute myeloid leukemia (AML) has relapsed or persisted despite earlier treatment....Roswell Park has begun patient recruitment for the study and initiated treatment for the first patient enrolled."

Trial status • Acute Myelogenous Leukemia